Shopping Cart
Remove All
Your shopping cart is currently empty
Ozoralizumab
🥰Excellent
Catalog No. T77126Cas No. 1167985-17-2
Alias TS-152, ATN-103
Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis.
Ozoralizumab
Ozoralizumab
🥰Excellent
Catalog No. T77126Alias TS-152, ATN-103Cas No. 1167985-17-2
Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $328 | In Stock | In Stock | |
| 5 mg | $859 | In Stock | In Stock | |
| 10 mg | $1,270 | In Stock | In Stock | |
| 25 mg | $1,890 | - | In Stock | |
| 50 mg | $2,550 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:95.6% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
| Description | Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis. |
| In vitro | METHODS: Ozoralizumab (ATN-103) (0.1-1000pM) was used to treat L929 cells and its high TNFα neutralizing potency was determined. RESULTS: Ozoralizumab (ATN-103) has high TNFα neutralizing potency, with very similar binding and dissociation properties, and KD values for human TNFα and monkey TNFα are 20.2 pM and 16.1 pM, respectively. [1] |
| In vivo | METHODS: Tg197 mice were injected subcutaneously with 1 mg/kg dose of Ozoralizumab (ATN-103) twice weekly to evaluate the formation of ADA against each anti-TNFα antibody and the effect of long-term administration of these anti-TNFα antibodies on TNFα-mediated TNFα in Tg197 mice. Efficacy of polyarthritis. RESULTS: Ozoralizumab (ATN-103) significantly and comparably reduced arthritis scores. [1] |
| Synonyms | TS-152, ATN-103 |
| Reactivity | Human |
| Verified Activity | The EC₅₀ is 0.004992 μg/mL. Immobilized human TNFa with target at 2 μg/mL can bind Ozoralizumab （VHH）. |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | ＜ 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Molecular Weight | 38.44 kDa |
| Cas No. | 1167985-17-2 |
| Color | Transparent |
| Appearance | Liquid |
Storage & Solubility Information
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Ozoralizumab | purchase Ozoralizumab | Ozoralizumab cost | order Ozoralizumab | Ozoralizumab in vivo | Ozoralizumab in vitro | Ozoralizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.